With the publication of the May 2014 update of the ASCO guidelines for the endocrine treatment of breast cancer, the phrase “5 years of adjuvant endocrine therapy for hormone receptor-positive breast cancer” has become “old hat”. According to the 2014 ASCO guidelines, the recommended duration of adjuvant endocrine therapy for patients with stage I-III hormone receptor-positive breast cancer is as follows: 1. Premenopausal or perimenopausal patients should be treated with triamcinolone for 5 years; after 5 years of triamcinolone, follow-up endocrine therapy should be given according to menstrual status. Continue to take triamcinolone for 5 years, for a total of 10 years; if after 5 years of triamcinolone, the menstrual status is determined to be menopausal, continue to take oral triamcinolone for a full 10 years, or switch to an aromatase inhibitor and continue to take it for 5 years, for a total of 10 years of triamcinolone and aromatase inhibitor. 2. Menopausal patients should be given triamcinolone for 10 years; or aromatase inhibitors for 5 years, and there is no sufficient basis to recommend oral aromatase inhibitors for a longer period (>5 years); or oral triamcinolone for 5 years, then convert to aromatase inhibitors and continue taking aromatase inhibitors for 5 years, for a total of 10 years of endocrine therapy; or triamcinolone for 2-3 years, then convert to aromatase inhibitors, continue to take aromatase inhibitors for 5 years, and accumulate 7-8 years of endocrine therapy. 3. Patients who have been menopausal but cannot tolerate triamcinolone acetonide or aromatase inhibitors: if they have taken aromatase inhibitors but discontinued treatment for less than 5 years, they can be given triamcinolone acetonide instead until the total time is 5 years; if they have taken triamcinolone acetonide for 2-3 years, they can be converted to aromatase inhibitors and take aromatase inhibitors for 5 years, with a total treatment time of 7-8 years. The above changes in the duration of endocrine therapy improve the overall and disease-free survival of hormone receptor-positive patients and reduce breast cancer mortality, the risk of recurrence, and the incidence of contralateral breast cancer; the downside is the increased risk of endometrial cancer, deep vein thrombosis, ischemic heart disease, and osteoporosis. However, overall, the benefits of prolonging the duration of endocrine therapy for hormone receptor-positive breast cancer patients far outweigh the disadvantages.